SonoTran® is currently being evaluated in a phase I/IIa multicentre clinical investigation in patients with metastatic colorectal cancer (mCRC). The trial includes three patient cohorts to evaluate (a) the safety of the SonoTran® Platform; (b) SonoTran®’s ability to enhance the delivery of cetuximab and irinotecan into tumours in resectable mCRC patients, and (c) SonoTran®’s ability to enhance tumour response to standard of care neoadjuvant chemotherapy (cetuximab + FOLFIRI) in unresectable first line mCRC patients.
Find out more about the ongoing clinical investigation here.
The coordinating investigator of the trial and the Oxford Churchill Hospital site principal investigator is Professor Rachel Kerr (Department of Oncology, University of Oxford). See here.